[go: up one dir, main page]

AR050673A1 - COMPOSITION PHARMACEUTICAL COMPOSITE BY BOTULIN TOXIN FOR THE TREATMENT OF PAIN IN THE JOINT OF THE KNEE BY COMPRESSION OF THE SAFEN NERVE - Google Patents

COMPOSITION PHARMACEUTICAL COMPOSITE BY BOTULIN TOXIN FOR THE TREATMENT OF PAIN IN THE JOINT OF THE KNEE BY COMPRESSION OF THE SAFEN NERVE

Info

Publication number
AR050673A1
AR050673A1 ARP050102648A ARP050102648A AR050673A1 AR 050673 A1 AR050673 A1 AR 050673A1 AR P050102648 A ARP050102648 A AR P050102648A AR P050102648 A ARP050102648 A AR P050102648A AR 050673 A1 AR050673 A1 AR 050673A1
Authority
AR
Argentina
Prior art keywords
knee
pain
compression
treatment
nerve
Prior art date
Application number
ARP050102648A
Other languages
Spanish (es)
Inventor
Kang Ahn
Original Assignee
Ipsen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd filed Critical Ipsen Ltd
Publication of AR050673A1 publication Critical patent/AR050673A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion farmacéutica compuesta por toxina botulínica y un portador farmacologicamente aceptable para el tratamiento del dolor en la articulacion de la rodilla, causado por el atrapamiento o la compresion del nervio safeno. La composicion de la presente es para aplicacion por inyeccion subcutánea, arriba de la cara medial de la rodilla.Pharmaceutical composition composed of botulinum toxin and a pharmacologically acceptable carrier for the treatment of pain in the knee joint, caused by entrapment or compression of the saphenous nerve. The composition of the present is for application by subcutaneous injection, above the medial aspect of the knee.

ARP050102648A 2004-06-28 2005-06-27 COMPOSITION PHARMACEUTICAL COMPOSITE BY BOTULIN TOXIN FOR THE TREATMENT OF PAIN IN THE JOINT OF THE KNEE BY COMPRESSION OF THE SAFEN NERVE AR050673A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040048889A KR100668570B1 (en) 2004-06-28 2004-06-28 Pharmaceutical composition comprising botulinum toxin for the treatment of knee joint pain by capturing nerve

Publications (1)

Publication Number Publication Date
AR050673A1 true AR050673A1 (en) 2006-11-15

Family

ID=35782045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102648A AR050673A1 (en) 2004-06-28 2005-06-27 COMPOSITION PHARMACEUTICAL COMPOSITE BY BOTULIN TOXIN FOR THE TREATMENT OF PAIN IN THE JOINT OF THE KNEE BY COMPRESSION OF THE SAFEN NERVE

Country Status (12)

Country Link
US (2) US20080199497A1 (en)
EP (1) EP1771195B1 (en)
JP (1) JP4933429B2 (en)
KR (1) KR100668570B1 (en)
AR (1) AR050673A1 (en)
CA (1) CA2571415C (en)
DK (1) DK1771195T3 (en)
ES (1) ES2625128T3 (en)
HU (1) HUE033364T2 (en)
PL (1) PL1771195T3 (en)
PT (1) PT1771195T (en)
WO (1) WO2006001676A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
ES2661033T3 (en) 2012-05-30 2018-03-27 President And Fellows Of Harvard College Genetically modified botulinum neurotoxin
WO2016002984A1 (en) * 2014-06-30 2016-01-07 (주)메디톡스 Pharmaceutical composition, for treating osteoarthritis, comprising botulinum toxin as active ingredient and osteoarthritis treatment method using same
CN115925835A (en) 2015-03-26 2023-04-07 哈佛大学校长及研究员协会 Engineered Botulinum Neurotoxin
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
KR102780506B1 (en) 2022-11-17 2025-03-12 홍약슬 Method and device for making artificial flower using biodegradable material

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
KR20040094756A (en) * 2002-03-01 2004-11-10 엘란 파마슈티칼스, 인크. Methods of Treating Nerve Entrapment Syndromes
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
WO2004075832A2 (en) * 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof

Also Published As

Publication number Publication date
JP4933429B2 (en) 2012-05-16
HUE033364T2 (en) 2017-11-28
US20090317426A1 (en) 2009-12-24
ES2625128T3 (en) 2017-07-18
PL1771195T3 (en) 2017-08-31
PT1771195T (en) 2017-06-05
JP2008504364A (en) 2008-02-14
KR20060000043A (en) 2006-01-06
KR100668570B1 (en) 2007-01-16
US20080199497A1 (en) 2008-08-21
US8337862B2 (en) 2012-12-25
EP1771195A1 (en) 2007-04-11
EP1771195A4 (en) 2010-08-18
CA2571415A1 (en) 2006-01-05
WO2006001676A1 (en) 2006-01-05
CA2571415C (en) 2016-10-04
DK1771195T3 (en) 2017-05-15
EP1771195B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
ATE430579T1 (en) TRANSDERMAL BOTULINUM TOXIN CONTAINING COMPOUNDS
MXPA03002576A (en) METHODS TO TREAT MUSCLE INJURIES.
BRPI0508440A (en) compositions and methods for topical diagnosis and therapeutic transport
DK1638586T3 (en) Synergistic composition for the treatment of diabetes mellitus
AR029464A1 (en) METHODS FOR THE TREATMENT OF DIABETES
SG160357A1 (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2011154126A3 (en) Skin antiaging treatment
ECSP056159A (en) CONJUGATED DRUG COMPOSITION
TN2009000124A1 (en) Injectable depot composition and its process of preparation
TW200612987A (en) Combination treatment for non-hematologic malignancies
NZ700623A (en) Botulinum toxin dosage regimen for chronic migraine prophylaxis
BRPI0518793A2 (en) Methods for treating, controlling or preventing an immunodeficiency disease or disorder, and for improving the immune response to an immunogen, and pharmaceutical composition.
BRPI0922789A2 (en) albumin binding peptide for disease recognition
BR112014007675A2 (en) degenerative joint disease treatment
BR0307496A (en) Use of a clostridial neurotoxin as well as pharmaceutical composition usable in the treatment of a mammary gland disorder
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
BRPI0516836A (en) cosmetic neurotoxin compositions comprising a botulinum toxin component and methods
AR050673A1 (en) COMPOSITION PHARMACEUTICAL COMPOSITE BY BOTULIN TOXIN FOR THE TREATMENT OF PAIN IN THE JOINT OF THE KNEE BY COMPRESSION OF THE SAFEN NERVE
MXPA06010767A (en) Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle.
FR2902341B1 (en) THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
WO2007087154A3 (en) Methods for enhancing therapeutic effects of a neurotoxin
Reebye et al. Module 2: nonsurgical management of spasticity
ATE554102T1 (en) THERAPEUTIC USES OF MONOCLONAL ANTIBODIES AGAINST THE ANGIOTENSIN-II TYPE-1 RECEPTOR
BR112021016795A8 (en) ADMINISTRATION OF JUICE ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS
DK1869185T3 (en) Conjugate with P21 protein for cancer treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal